Bioscience Advising Academic Proofreading Editor

  • Home >>

About Our Academic Proofreading Services:

Bioscience Advising is an internationally-recognized biomedical research consultancy with a specific focus on the preparation/editing of all types of research documents. The company is based in Ypsilanti, MI. We are committed to adhering to the highest standards in editing, developing, critiquing and refining your documents for the greatest optimization of publication (in respected journals), or achieving successful research funding.

Curt Balch, PhD

BioScience Advising

facebook Linkedin

Dr. Balch coordinates company business, customer service, and peer review. He is currently a Research Scholar at the Ronin Institute and The Complex Biological Systems Alliance. He was previously employed for ten years as a faculty member of the Indiana University School of Medicine, where he remains an adjunct faculty member. Curt was also an adjunct senior research at the University of Toledo, Department of Pharmacology. He received his Ph.D\in biochemistry and molecular biology from the University of Cincinnati (UC), followed by postdoctoral training in protein biochemistry, epigenetics, and cancer biology at UC and Indiana University.

In addition to five years of employment in the biotechnology industry, he has authored over 30 peer-reviewed basic and translational research publications (see curriculum vitae), and has also served as a reviewer for numerous well-respected biomedical research journals, including Clinical Cancer Research, Cancer Research, and the Journal of Urology.

Moreover, with over seven years of service on National Cancer Institute review committees, Curt is intimately familiar with the peer-review process and the required attributes of successfully funded grant applications. That experience has resulted in his receipt of three funding awards for his own independent research. Finally, in separate work in the biotechnology industry, his consultation on grant preparation has led to the successful funding of four small business research innovation (SBIR) awards.

Selected Publications Edited by Bioscience Advising

Choi SH, et al., 2019. Temporal and differential regulation of KAISO-controlled transcription by phosphorylated and acetylated p53 highlights a crucial regulatory role of apoptosis. J Biol Chem 120(5): 488-498.

Jeon BN, et al. 2019. Derepression of matrix metalloproteinase gene transcription and an emphysema-like phenotype in transcription factor Zbtb7c knockout mouse lungs. FEBS Lett 593(18):2665-2674.

Song JY, et al., 2019. HIC2, a new transcription activator of SIRT1. FEBS Lett 593(14):1763-1776.

Su PH, Balch, et al., 2019. TET1 promotes 5hmC-dependent stemness, and inhibits a 5hmC-independent epithelial-mesenchymal transition, in cervical precancerous lesions. Cancer Lett Epub Feb 13, 2019.

Moon S, Balch, et al., 2019. Systematic inspection of the clinical relevance of TP53 missense mutations in gastric cancer. IEEE/ACM Trans Comput Biol Bioinform 16(5):1693-1701.

Kim JH et al., 2019. Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015. Br J Cancer 120(5): 488-498.

Choi SH et al., 2019. Hypoxia-induced RelA/p65 derepresses SLC16A3 (MCT4) by downregulating ZBTB7A. Biochim Biophys Acta Gene Regul Mech 1862(8):771-785.

Kim et al., 2015. Effects of low-fat diet and aging on metabolic profiles of Creb3l4 knockout mice. Nutr Diabetes5:e179. doi 10.1038.

Yeh et al., 2015. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma. Oncotarget 2015 July 22 [Epub ahead of print].

Koh et al., 2015. Transcriptional activation of Apaf1 by KAISO (ZBTB33) and p53 is attenuated by RelA/p65. Biochim Biopys Acta 1849(9): 1170.

Zu et al., 2015. Platelet-derived growth factor-BB enhances MSC-mediated cardioprotection via suppression of miR-320 expression. Am J Physiol Heart Circ Physiol 308(9): H980.

Park et al., 2015. Network comparison of inflammation in colorectal cancer and Alzheimer’s disease. Biomed Res Intl 2015:205247. doi: 10.1155/2015/205247. Epub 2015 Jul 26.

Kim et al., 2014. ZBTB2 increases PDK4 expression by transcriptional repression of RelA/p65. Nucleic Acids Res43(3): 1609.

Koh et al., 2014. KAISO, a critical regulator of p53-mediated transcription of CDKN1A and apoptotic genes. Proc Natl Acad Sci 111(42): 15078.

Choi et al., 2014. Promyelocytic leukemia zinc finger-retinoic acid receptor alpha, an oncogenic transcriptional respressor of cyclin-dependent kinase inhibitor 1A (p21WAF/CDKN1A) and tumor protein p53 (TP53) genes. J Biol Chem 289(27): 18641.

Choi et al., 2104. Role of promyelocytic leukemia zinc finger (PLZF) in cell proliferation and cyclin-ddependent inhibitor 1A (p21WAF/CDKN1A) gene repression. J Biol Chem 289(7): 18625.

Koh et al., 2014. Kaiso is a key regulator of spleen germinal center formation by repressing Bcl6 expression in splenocytes. Biochem Biophys Res Commun: 442(3-4): 177.

Chang et al., 2014. HNF4-alpha is a therapeutic target that links AMPK to WNT signaling in early-stage gastric cancer. Gut 2014;0:1–14. doi:10.1136.

Publications Written by Bioscience Advising

Todorova K and Mandinova A., 2020. Drug discovery for aged skin and nonmelanoma skin cancer. Adv Drug Deliv Rev, under revision.

Kim, Balch, et al., 2020. Design of small molecules for a promising druggable target, RhoA, for the therapy of gastric cancer. The Pharmacogenomics J., in press.

Nam et al., 2015. A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer. Cancer Lett 356(2 Pt B):88

Successfully Funded Grant Applications Edited by Bioscience Advising

1R01AR07542101. Posttranscriptional control of epidermal progenitor senescence. Anna Mandinova, Principal Investigator,  $381,625 (FY 2019)

5R01ES023569-05. Trinucleotide repeat instability via DNA damage and repair. Yuan Liu, Principal Investigator, $320,278 (FY 2018)

Vascular AT2R expression and function during pregnancy, Sathish Kumar, Principal Investator, $382,500 (FY 2018)

Mechanisms of beta cell function in health and disease. Carmella Evans-Molina, Principal Investigator, $401,963 (FY 2017)

A transformational bioinformatics approach for drug interaction research. Dr. Lang Li, Principal Investigator, $362,872 (FY2015)

DNA methylation and ovarian cancer, Kenneth Nephew, Principal Investigator, $233,593 (FY 2012)